Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Payables: 2018-2024

Historic Payables for Whitehawk Therapeutics (WHWK) over the last 7 years, with Dec 2024 value amounting to $2.2 million.

  • Whitehawk Therapeutics' Payables rose 18.85% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 14.60%. This contributed to the annual value of $2.2 million for FY2024, which is 63.39% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Payables of $2.2 million as of FY2024, which was down 63.39% from $5.9 million recorded in FY2023.
  • Whitehawk Therapeutics' Payables' 5-year high stood at $11.4 million during FY2020, with a 5-year trough of $2.2 million in FY2024.
  • Over the past 3 years, Whitehawk Therapeutics' median Payables value was $3.5 million (recorded in 2022), while the average stood at $3.9 million.
  • In the last 5 years, Whitehawk Therapeutics' Payables soared by 253.43% in 2020 and then slumped by 63.39% in 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Payables (Yearly) stood at $11.4 million in 2020, then crashed by 43.62% to $6.4 million in 2021, then tumbled by 45.35% to $3.5 million in 2022, then spiked by 67.60% to $5.9 million in 2023, then slumped by 63.39% to $2.2 million in 2024.